衰弱与共病对英国生物银行社区COVID-19死亡预测:采样效应
基于英国生物银行410199名49-86岁社区人群及2812例COVID-19住院患者,评估衰弱与共病指标对COVID-19死亡的预测能力。社区全样本中,与疫情同步评估的医院衰弱风险评分(HFRS)和Charlson共病指数(CCI)与死亡风险关联更强,且显著提升预测模型AUC至0.8以上;住院患者中未见类似提升。
要点
- 社区人群中,与疫情同步评估的HFRS高(>15)vs低(<5)的COVID-19死亡OR为20.40(95%CI 16.24-25.63)。
- 同步CCI每增加1分,COVID-19死亡OR为1.53(95%CI 1.48-1.59)。
- 仅同步HFRS或CCI显著改善含年龄和性别模型的预测能力,AUC>0.8;住院患者中无此改善。
核心结论
- 与疫情同步从医疗记录构建的HFRS和CCI可用于人群层面COVID-19死亡风险分层。
- 在COVID-19住院患者中,这些指标的附加预测价值有限。
研究设计与样本
- 基于人群的队列研究,分析英国生物银行英格兰410199名49-86岁参与者全样本及2812例COVID-19住院患者子样本。
主要发现
- 全样本共514人死于COVID-19。
- 调整年龄和性别后,所有衰弱和共病指标均与COVID-19死亡风险升高相关。
- 同步HFRS高(>15)vs低(<5)的OR为20.40(95%CI 16.24-25.63),同步CCI每分OR为1.53(95%CI 1.48-1.59)。
- 仅同步HFRS或CCI显著改善含年龄和性别模型的预测能力,AUC>0.8。
- 限制于COVID-19住院患者时,未观察到类似的AUC改善。
关键数值与推荐
- 衰弱定义采用物理衰弱表型(PFP)、衰弱指数(FI)和医院衰弱风险评分(HFRS)。
- 共病采用Charlson共病指数(CCI)。
- PFP和FI仅在基线可用,HFRS和CCI在基线和疫情开始时同步评估。
临床怎么用
- 在社区人群中,可利用与疫情同步的HFRS和CCI进行COVID-19死亡风险分层。
- 对COVID-19住院患者,HFRS和CCI的附加预测价值有限,需结合其他评估。
局限性
- PFP和FI仅在基线可用,无法评估同步变化。
- 研究样本为英国生物银行参与者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Frailty has been linked to increased risk of COVID-19 mortality, but evidence is mainly limited to hospitalized older individuals. This study aimed to assess and compare predictive abilities of different frailty and comorbidity measures for COVID-19 mortality in a community sample and COVID-19 inpatients. DESIGN: Population-based cohort study. SETTING: Community. PARTICIPANTS: We analyzed (i) the full sample of 410,199 U.K. Biobank participants in England, aged 49-86 years, and (ii) a subsample of 2812 COVID-19 inpatients with COVID-19 data from March 1 to November 30, 2020. MEASUREMENTS: Frailty was defined using the physical frailty phenotype (PFP), frailty index (FI), and Hospital Frailty Risk Score (HFRS), and comorbidity using the Charlson Comorbidity Index (CCI). PFP and FI were available at baseline, whereas HFRS and CCI were assessed both at baseline and concurrently with the start of the pandemic. Inpatient COVID-19 cases were confirmed by PCR and/or hospital records. COVID-19 mortality was ascertained from death registers. RESULTS: Overall, 514 individuals died of COVID-19. In the full sample, all frailty and comorbidity measures were associated with higher COVID-19 mortality risk after adjusting for age and sex. However, the associations were stronger for the concurrent versus baseline HFRS and CCI, with odds ratios of 20.40 (95% confidence interval = 16.24-25.63) comparing high (>15) to low (<5) concurrent HFRS risk category and 1.53 (1.48-1.59) per point increase in concurrent CCI. Moreover, only the concurrent HFRS or CCI significantly improved predictive ability of a model including age and sex, yielding areas under the receiver operating characteristic curve (AUC) >0.8. When restricting analyses to COVID-19 inpatients, similar improvement in AUC was not observed. CONCLUSION: HFRS and CCI constructed from medical records concurrent with the start of the pandemic can be used in COVID-19 mortality risk stratification at the population level, but they show limited added value in COVID-19 inpatients.
引用
- Mak JKL, Kuja-Halkola R, Wang Y, et al. Frailty and comorbidity in predicting community COVID-19 mortality in the U.K. Biobank: The effect of sampling. J Am Geriatr Soc. 2021. PMID: 33619733. doi:10.1111/jgs.17089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。